Bosh sahifaAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
24,86 $
Seans yopilganidan keyin:(4,58%)-1,14
23,72 $
Yopilgan:16-may, 18:43:06 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
24,32 $
Kunlik diapazon
24,20 $ - 24,90 $
Yillik diapazon
22,64 $ - 53,96 $
Bozor kapitalizatsiyasi
1,17 mlrd USD
Oʻrtacha hajm
639,87 ming
Narx/foyda
9,02
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 170,53 mln | -0,76% |
Joriy xarajat | 47,96 mln | 13,94% |
Sof foyda | 25,28 mln | -41,44% |
Sof foyda marjasi | 14,83 | -40,99% |
Har bir ulushga tushum | 0,74 | -28,85% |
EBITDA | 50,90 mln | -16,54% |
Amaldagi soliq stavkasi | 18,07% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 236,88 mln | -18,19% |
Jami aktivlari | 1,63 mlrd | 3,30% |
Jami passivlari | 874,99 mln | -2,99% |
Umumiy kapital | 751,28 mln | — |
Tarqatilgan aksiyalar | 47,14 mln | — |
Narxi/balansdagi bahosi | 1,54 | — |
Aktivlardan daromad | 5,82% | — |
Kapitaldan daromad | 6,69% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 25,28 mln | -41,44% |
Operatsiyalardan naqd pul | 35,08 mln | -36,56% |
Sarmoyadan naqd pul | 10,48 mln | -31,21% |
Moliyadan naqd pul | -14,50 mln | -6,80% |
Naqd pulning sof oʻzgarishi | 31,17 mln | -45,17% |
Boʻsh pul | 16,94 mln | -57,15% |
Haqida
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Tashkil etilgan
1996
Sayt
Xodimlar soni
2 028
